Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05678673 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Study acronym: STELLAR-304
StatusActive, Not Recruiting
PhasePhase 3
SponsorExelixis
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 4 months later Jul 2025 → Dec 15, 2026
See other at-risk trials from Exelixis

Record History

  1. Primary completion pushed from Jul 2025 to Dec 15, 2026 Completion date: Jun 2028 to Jun 30, 2028v11 Show 1 more changeShow less
    • Completion date: Jun 2028 to Jun 30, 2028
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 291 to confirmed 317 · Study sites: 164 to 163v10 Show 2 more changesShow less
    • Enrollment target: estimated 291 to confirmed 317
    • Study sites: 164 to 163
  3. Study sites: 87 to 164v9
  4. Study sites: 16 to 87v8
  5. Study sites: 10 to 16v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 5 to 10v6
  2. Study sites: 3 to 5v5
  3. Study sites: 2 to 3v4
  4. Study sites: 1 to 2 Start date changed from estimate of Jan 2023 to Jan 1, 2023v3 Show 1 more changeShow less
    • Start date changed from estimate of Jan 2023 to Jan 1, 2023
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date: Feb 2023 to Jan 2023v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date: Feb 2023 to Jan 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exelixis
25 trials monitored
See 2 trials at risk
Kidney Cancer
772 trials monitored
See 53 trials at risk
This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.
Trial Details
NCT Number NCT05678673
Lead Sponsor Exelixis
Conditions Non-Clear Cell Renal Cell Carcinoma
Enrollment 317 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov